Kali Therapeutics Receives U.S. FDA Clearance for KT501 Investigational New Drug Application

RegulatoryapprovedKT501Positive

AI Analysis

Summary

Kali Therapeutics received FDA clearance for the Investigational New Drug Application of KT501, a first-in-class tri-specific T-cell engager for B cell-mediated autoimmune diseases, enabling U.S. clinical development based on ongoing safety data from an Australian first-in-human study.

Clinical Trial Data

Phase

Phase 1

Outcome Details

U.S. FDA IND clearance granted for KT501

Importance:7/10

Sentiment:

0.80

IND clearanceCD19xBCMAxCD3 tri-specific T-cell engagerautoimmune diseaserheumatoid arthritisfirst-in-classregulatory approval

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on September 3, 2026 3:16 PM

Read Original